Drug intelligence / Profile preview

milbemycin oxime

Development stage
Unknown
Lead developer
Elanco
Modality
Small Molecules
Administration
Oral
01

Overview

Milbemycin oxime is a broad-spectrum antiparasitic drug from the milbemycin class used primarily in veterinary medicine. It is effective against a range of nematodes (including heartworms, hookworms, roundworms, and whipworms) and some mites (such as Sarcoptes and Demodex). The drug acts by binding to glutamate-gated chloride channels on parasite nerve and muscle cells. This increases the permeability of these membranes to chloride ions via enhanced release of the inhibitory neurotransmitter GABA. The resulting disruption in nerve signal transmission leads to neuro-paralysis and death of the parasites. Milbemycin oxime is FDA-approved for prevention of heartworm disease in dogs and cats but is less potent against heartworm than ivermectin. It is also used off-label for mite infestations in dogs[1][2][4][6].

Brand names
InterceptorMilbeGuardInterceptor PlusSentinel Flavor TabsTrifexisNexgard Spectra
02

Targets

RDL (Insect GABA-gated chloride channel)GluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on milbemycin oxime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on milbemycin oxime.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call